Text Size

The Safety of Cataract Removal by Phacoemulsification Surgery in Patients Under Anti-aggregant and Coumadin Treatment

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2009 by Sheba Medical Center.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Sheba Medical Center
ClinicalTrials.gov Identifier:
NCT00564356
First received: November 26, 2007
Last updated: July 19, 2009
Last verified: July 2009
History of Changes
  Purpose

To assess the risks of intra- and postoperative bleeding tendency associated with cataract surgery by phacoemulsification in patients on coumadin and antiaggregant treatments.

Design: Consecutive prospective study.


Condition Intervention
Efficacy
Complications
 Procedure: cataract surgery with phacoemulsification

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: The Safety of Cataract Removal by Phacoemulsification Surgery in Patients Under Anti-aggregant and Coumadin Treatment

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Sheba Medical Center:

Primary Outcome Measures:
  • safety and efficacy of cataract surgery with phacoemulsification under coumadin and antiaggregant treatment [ Time Frame: 3.5 years ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • other complications [ Time Frame: 3.5 years ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 75
Study Start Date: July 2007
Estimated Study Completion Date: December 2010
Primary Completion Date: August 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
A
patients under coumadin and antiaggregants operated by phacoemulsification
 Procedure: cataract surgery with phacoemulsification
removal of cataract with phacoemulsification technique

Detailed Description:

To assess the risks of intra- and postoperative bleeding tendency associated with cataract surgery by phacoemulsification technique in patients on coumadin and antiaggregant treatment Design: Consecutive prospective study.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • patients who give informed consent to participate in the study

Exclusion Criteria:

  • single eye complicated cataract
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00564356

Contacts
Contact: Ophira Salomon, MD 972-3-5302104 ophiras@sheba.health.gov.il
Contact: Yael Wasserzug, MD 972-3-5302874 yawlwasserzug@gmail.com

Locations
Israel
Sheba Medical Center Recruiting
Ramat-Gan, Israel
Sub-Investigator: Irina Barequet, md            
Sub-Investigator: Joseph Moisseiev, MD            
Sponsors and Collaborators
Sheba Medical Center
Investigators
Study Director: Ophira Salomon Sheba Medical Center
  More Information

Additional Information:
The safety and efficacy of cataract surgery under coumadin treatment  This link exits the ClinicalTrials.gov site

Publications:

Responsible Party: Sheba Medical Center
ClinicalTrials.gov Identifier: NCT00564356     History of Changes
Other Study ID Numbers: SHEBA-07-3017-OS-CTIL
Study First Received: November 26, 2007
Last Updated: July 19, 2009
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Keywords provided by Sheba Medical Center:
cataract, phacoemulsification, coumadin, antiaggregants

Additional relevant MeSH terms:
Cataract
Lens Diseases
Eye Diseases
Warfarin
 Anticoagulants
Hematologic Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on May 22, 2013